Prognostic accuracy of inflammatory markers in predicting risk of ICU admission for COVID-19: application of time-dependent receiver operating characteristic curvesCOVID-19에 대한 ICU 입원 위험 예측에서 염증 표지자의 예후 정확도: 시간 종속 수신기 작동 특성 곡선의 적용Observational Study Published on 2022-06-012022-09-11 Journal: The Journal of international medical research [Category] MERS, 바이오마커, 임상, [키워드] 95% CI 95% confidence interval Accuracy Admission approach Ayatollah baseline level baseline levels C-reactive protein C-reactive protein (CRP Care characteristic COVID-19 COVID-19 infection CRP cutoff value evaluate evaluated greater hazard ratio Hospital admission Hospitalization ICU ICU admission Inflammatory marker inflammatory markers intensive care intensive care unit intensive care unit admission Iran lymphocyte Medical Sciences neutrophil Neutrophil-to-lymphocyte ratio NLR observational study occur outcome Patient patients with COVID-19 predictor reached receive receiver operating characteristic receiver operating characteristic curve referred to risk ROC ROC Curve ROC curves severe COVID-19 Severe COVID-19 Infection significantly Stratification time-dependent area under the receiver operating characteristic curve. time-dependent ROC curve university [DOI] 10.1177/03000605221102217 PMC 바로가기 [Article Type] Observational Study
Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trialClinical Trial Published on 2022-06-012022-10-04 Journal: Radiotherapy and oncology : journal of the Europea [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] age baseline Benign Benign disease Blood C-reactive protein causes changes in Clinical improvement conducted COVID COVID-19 COVID-19 patient CTCAE decrease Descriptive analysis died discharged Efficacy evaluate extension feasible ferritin Follow-up fraction hospital Hospitalization Inflammatory interquartile range IQR LD-RT LDH low-dose lung lung involvement lymphocyte Lymphocytes management material median outcome Oxygen requirement oxygen saturation parameter Patient patients with COVID-19 Pneumonia Radiation radiation therapy radiological randomized trial Remdesivir required Respiratory failure SAFI secondary severity Significant significantly square Standard deviation steroid Tocilizumab Toxicity treat Treatment Trial variables was used [DOI] 10.1016/j.radonc.2022.03.015 PMC 바로가기 [Article Type] Clinical Trial
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients노르웨이의 COVID-19 환자의 입원 기간 및 중환자실 입원 및 병원 내 사망 위험: mRNA 백신으로 완전히 예방접종을 받은 환자와 예방접종을 받지 않은 환자를 비교한 등록 기반 코호트 연구Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted Admission age analyzed Birth Breakthrough infection cohort study country COVID-19 patient Cox proportional hazard Cox proportional hazards models dose hazard ratio Health authority hospital Hospital stay Hospitalization Hospitalized hospitals ICU ICU admission In-hospital In-hospital death intensive care intensive care unit Length Length of stay log lower risk management median mRNA vaccine National no difference Norway Patient Patient management patients patients hospitalized registry data residence risk Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-positive patient SARS-CoV-2-positive patients Sex Support vaccination Vaccination Status variant virus with COVID-19 [DOI] 10.1016/j.cmi.2022.01.033 PMC 바로가기 [Article Type] Article
Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity폐 계면활성제의 감소된 DMPC 및 PMPC는 비만에서 SARS-CoV-2 감염을 촉진합니다Article Published on 2022-06-012022-09-11 Journal: Metabolism: clinical and experimental [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 ACE2 expression ACE2 receptor Analysis BALF bind Bronchoalveolar lavage fluid cell-cell fusion assay characterized cholesterol COVID-19 COVID-19 disease COVID-19 pneumonia D614G mutant SARS-CoV-2 Defense DMPC Effect effector cells elevated expressing fat Feeding HEK293T HEK293T cell HEK293T cells High fat diet Hospitalization increased risk Increasing Infection infections inhibited inhibitory effect Inhibitory effects Lipid lipid composition lipid metabolism lipids lung lung surfactant lung tissue Lungs mechanism metabolism mice myristic acid obese obesity outcomes overexpression Phosphatidylcholine Pneumocytes produced promote Protein reduced respiratory virus reversed risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pseudovirus infection SARS-CoV-2 viral loads severe COVID-19 disease Severe COVID-19 pneumonia Spike protein surfactant the Spike Triglyceride triglycerides trimyristin Type II pneumocyte type II pneumocytes Vero-E6 cell Vero-E6 cells was performed were used wild type [DOI] 10.1016/j.metabol.2022.155181 PMC 바로가기 [Article Type] Article
COVID-19 complications in males and females: recent developmentsReview Published on 2022-06-012023-07-09 Journal: Journal of Comparative Effectiveness Research [Category] COVID19(2023년), [키워드] COVID-19 Gender Hospitalization Mortality SARS-CoV-2 Sex. [DOI] 10.2217/cer-2022-0027 PMC 바로가기 [Article Type] Review
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccineSinopharm/BBIBP-CorV 백신에 대한 면역 반응의 지속성Article Published on 2022-06-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ACE2 age all age groups angiotensin Angiotensin-converting enzyme antibody Antibody Response Antibody responses assays blocking antibodies Cell Cohort COVID-19 declined detectable determine Efficacy ELISPOT ELISpot assays enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Ex vivo group groups Hospitalization immune response immune responses Immunity individual individuals interferon gamma investigated Kinetics long term memory B memory B cell overlapping peptide peptides persistence Protein RBD receptor Receptor-binding domain remained response SARS-CoV-2 second dose severe disease Sinopharm Sinopharm/BBIBP-CorV Spike protein T cell T cell response T cell responses the RBD the receptor-binding domain the spike protein the vaccine total antibodies total antibody Vaccine Vaccines variants variants of concern virus were assessed were measured [DOI] 10.1002/iid3.621 PMC 바로가기 [Article Type] Article
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness백신 효과에 대한 델타(B.1.617.2) 변이체의 출현의 의미Review Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Administered analyzed article assist AstraZeneca B.1.617.2 breakthrough infections concern convalescent patient Convalescent patients COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta delta variant Delta variants determine disease severity effective Effectiveness Efficacy FIVE Hospitalization in vitro in vivo incidence infection with SARS-CoV-2 Meta-analysis Moderna neutralization neutralizing antibody Oxford-AstraZeneca pandemic Pfizer Pfizer-BioNTech reduced reducing reductions in SARS-CoV-2 SARS-CoV-2 pandemic screened searched second dose significant reductions significantly symptomatic infection Transmission vaccinated individual vaccinated individuals vaccination Vaccinations Vaccine Vaccines variant variants [DOI] 10.1007/s15010-022-01759-1 PMC 바로가기 [Article Type] Review
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial
Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations심각한 COVID-19 3개월 후 호흡기 기능 장애는 장내 미생물 변화와 관련이 있습니다Article Published on 2022-06-012022-09-11 Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 16S rRNA 16S rRNA gene alteration Analysis analyzed Bacterial carbon monoxide collected coronavirus disease Coronavirus disease 2019 COVID COVID-19 COVID-19 patient defined diffusing diffusing capacity disease severity dysfunction elevated Evidence fibrosis FIVE Follow-up gastrointestinal tract Gut gut microbiota gut microbiota composition gut-lung axis Hospital admission Hospitalization Hypothesis Inflammation investigated involved kPa LBP limit lipopolysaccharide low-grade inflammation lung Lungs marker Microbiome microbiota P/F ratio Patient plasma Protein pulmonary dysfunction Pulmonary function Rectal swabs reduced remained respiratory Respiratory failure respiratory infection rRNA SARS-CoV-2 Sequencing severe COVID-19 Swab the disease Trial was collected was reduced [DOI] 10.1111/joim.13458 PMC 바로가기 [Article Type] Article
A case series of severe breakthrough infections observed in nine patients with COVID-19 in a southwestern German university hospital독일 남서부 대학 병원에서 9명의 COVID-19 환자에서 관찰된 일련의 심각한 돌발 감염 사례Article Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), SARS, 변종, [키워드] addition advanced age age analyzed avoidance B.1.617.2 behavioural BNT162b2 BNT162b2 vaccines booster vaccination Breakthrough infection cardiorespiratory case sery Comorbidities Complete Course COVID-19 death delta variant disease dose effective Face masks FIVE high risk high-risk area high-risk areas Hospitalization Hospitalized hospitalized patient immunization Increased Infection Intensive intensive care lack measure Measures median median age nine of BNT162b2 Patient patients patients died patients with COVID-19 Pfizer-BioNTech preventive measures Protective question raise risk factor Risk factors SARS-CoV-2 suffered symptom onset Travel two patients U/mL university hospital vaccination Vaccine Vaccine breakthrough [DOI] 10.1007/s15010-022-01797-9 PMC 바로가기 [Article Type] Article